These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28012206)

  • 1. Uptake and efflux kinetics, and intracellular activity of voriconazole against Aspergillus fumigatus in human pulmonary epithelial cells: a new application for the prophylaxis and early treatment of invasive pulmonary aspergillosis.
    Wang T; Yang Q; Chen L; Li Y; Meng T; Wang Y; Zhang T; Lei J; Xing J; Dong Y
    Fundam Clin Pharmacol; 2017 Jun; 31(3):311-318. PubMed ID: 28012206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.
    Wang T; Zhang T; Meng T; Li Y; Chen L; Yang Q; Dong H; Lei J; Chen L; Dong Y
    J Transl Med; 2018 Jun; 16(1):157. PubMed ID: 29880050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of voriconazole in a dynamic in vitro model of invasive pulmonary aspergillosis: implications for in vitro susceptibility breakpoints.
    Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Majithiya JB; Lass-Flörl C; Cuenca-Estrella M; Arendrup MC; Warn PA; Hope WW
    J Infect Dis; 2012 Aug; 206(3):442-52. PubMed ID: 22634880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasive aspergillosis in a paediatric allogeneic stem cell transplantation recipient owing to a susceptible Aspergillus fumigatus: Treatment failure with high doses of voriconazole and influence of CYP2C19 polymorphisms.
    Cendejas-Bueno E; Borobia AM; Gomez-Lopez A; Escosa-García L; Río-García M; Plaza D; García-Rodriguez J; Carcas-Sansuán A
    Int J Antimicrob Agents; 2016 May; 47(5):410-1. PubMed ID: 27056297
    [No Abstract]   [Full Text] [Related]  

  • 6. APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
    Zhao M; Lepak AJ; Marchillo K; Vanhecker J; Sanchez H; Ambrose PG; Andes DR
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy of advanced invasive pulmonary aspergillosis in transiently neutropenic rats using human pharmacokinetic equivalent doses of voriconazole and anidulafungin.
    van de Sande WW; Mathot RA; ten Kate MT; van Vianen W; Tavakol M; Rijnders BJ; Bakker-Woudenberg IA
    Antimicrob Agents Chemother; 2009 May; 53(5):2005-13. PubMed ID: 19237647
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Kimura G; Nakaoki T; Colley T; Rapeport G; Strong P; Ito K; Kizawa Y
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invasive pulmonary aspergillosis due to a multi-azole resistant Aspergillus fumigatus.
    Jeurissen A; Cooreman S; Van Kerckhoven W; Van Leemput J; Vanhove P; Lagrou K; Heytens L
    Acta Clin Belg; 2012; 67(1):46-8. PubMed ID: 22480040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive pulmonary aspergillosis in patients with solid tumours: risk factors and predictors of clinical outcomes.
    Dandachi D; Wilson Dib R; Fernández-Cruz A; Jiang Y; Chaftari AM; Hachem R; Raad I
    Ann Med; 2018 Dec; 50(8):713-720. PubMed ID: 30230385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
    Lamaris GA; Ben-Ami R; Lewis RE; Kontoyiannis DP
    J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subacute invasive pulmonary aspergillosis as a rare cause of pneumothorax in immunocompetent patient: brief report.
    Vukicevic TA; Dudvarski-Ilic A; Zugic V; Stevanovic G; Rubino S; Barac A
    Infection; 2017 Jun; 45(3):377-380. PubMed ID: 28233110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Multimodal Imaging Approach Enables
    Poelmans J; Himmelreich U; Vanherp L; Zhai L; Hillen A; Holvoet B; Belderbos S; Brock M; Maertens J; Vande Velde G; Lagrou K
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29760132
    [No Abstract]   [Full Text] [Related]  

  • 15. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model--authors' response.
    Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
    J Antimicrob Chemother; 2015 Feb; 70(2):634-5. PubMed ID: 25488075
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of a human small airway epithelial cell line to study the interactions of
    Liu H; Lin J; Phan QT; Gravelat FN; Sheppard DC; Filler SG
    mSphere; 2023 Oct; 8(5):e0031423. PubMed ID: 37578262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posaconazole pharmacodynamic target determination against wild-type and Cyp51 mutant isolates of Aspergillus fumigatus in an in vivo model of invasive pulmonary aspergillosis.
    Lepak AJ; Marchillo K; Vanhecker J; Andes DR
    Antimicrob Agents Chemother; 2013 Jan; 57(1):579-85. PubMed ID: 23147740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic effects of pentoxifylline on invasive pulmonary aspergillosis in immunosuppressed mice.
    Feng C; Zhang M; Zhang S; Zhang J; Li C; Zhou J
    BMC Pulm Med; 2021 Jan; 21(1):31. PubMed ID: 33468116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of fungicidal activities of voriconazole and amphotericin B against hyphae of Aspergillus fumigatus.
    Krishnan S; Manavathu EK; Chandrasekar PH
    J Antimicrob Chemother; 2005 Jun; 55(6):914-20. PubMed ID: 15824093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
    Denning DW; Ghnan N; Kwizera R; Osmanov A
    J Antimicrob Chemother; 2015 Feb; 70(2):633. PubMed ID: 25151206
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.